Import from '@womanrx/ui'

Sermorelin + Thymosin Alpha-1 Stack: Safety and Monitoring for Women

What This Stack Is and Why Women Ask About It

Sermorelin and thymosin alpha-1 target two distinct physiological axes. Sermorelin stimulates your pituitary to release growth hormone (GH) in a pulsatile, feedback-regulated way. Thymosin alpha-1, a 28-amino-acid peptide originally isolated from thymic tissue, modulates T-cell differentiation and innate immune signaling. Women who contact telehealth providers about this combination often frame it around three goals: improving body composition as GH secretion naturally declines with age, supporting immune function during the immune remodeling of perimenopause, and accelerating recovery from illness or intense training.

The appeal is understandable. GH secretion in women declines approximately 14% per decade after age 30, meaning a 45-year-old woman has roughly half the GH pulse amplitude she had at 20. Thymosin alpha-1 has an established track record in immunocompromised populations, with thymalfasin approved in 37 countries for hepatitis B and hepatitis C adjunct therapy, though it is not FDA-approved in the United States for any indication. Sermorelin holds an FDA approval history for growth hormone deficiency in children but is currently compounded for adult use under 503A/503B pharmacy regulations.

Before treating this combination as established medicine, you need the full picture of what is known, what is extrapolated, and what is simply unknown, especially for women.

The Evidence Gap: What Is Directly Studied vs. Extrapolated

This matters. Women were systematically underrepresented in early peptide trials, and virtually no peer-reviewed data exists on the sermorelin-plus-thymosin-alpha-1 combination specifically.

What Has Been Directly Studied

Sermorelin monotherapy in adults with GH deficiency showed improvements in lean body mass and fat mass in small trials, but most enrolled predominantly male subjects. A 6-month study by Prakash and Bhatt (2015) found sermorelin increased IGF-1 levels with an acceptable side-effect profile, though women-specific data were not separated. Thymosin alpha-1 has the strongest human evidence base in chronic hepatitis and cancer chemotherapy-induced immunosuppression. A Cochrane-adjacent systematic review by Shen et al. In Oncotarget (2018) reported that thymalfasin reduced infection rates in cancer patients receiving chemotherapy, with a relative risk of 0.71 for serious infection. Neither compound has been studied together in a prospective human trial.

What Is Extrapolated

The reasoning behind stacking them goes like this: because the two peptides work on separate receptor systems (GHRH-R for sermorelin; toll-like receptor 9 and T-cell co-stimulatory pathways for thymosin alpha-1), the assumption is low pharmacokinetic interaction risk. That assumption comes from mechanism, not from drug-drug interaction studies. Animal data in rodents support independent action, but rodent GH biology differs substantially from human female GH biology, which is shaped by estrogen-driven GH pulse patterns.

The Honest Bottom Line on Evidence

The combination is used in clinical practice by some compounding-friendly providers, but that does not make it evidence-based for women. If your provider cannot explain the specific physiological rationale for your life stage, that is a red flag.

How Sermorelin Works in the Female Body

Sermorelin is not synthetic GH. It stimulates your own pituitary to release GH, preserving the negative-feedback loop that direct GH injections bypass. This matters because the risk of supraphysiologic GH (and subsequent IGF-1 excess) is lower with sermorelin than with exogenous recombinant GH.

Estrogen's Relationship With GH Secretion

Estrogen directly amplifies GH pulse amplitude. Women in their reproductive years have higher GH secretion than age-matched men, largely because of estrogen's action on the somatotroph cells of the pituitary. Veldhuis et al. Demonstrated that estradiol infusion in postmenopausal women restored GH pulse amplitude toward premenopausal values, confirming that estrogen status changes your baseline GH physiology. This has a direct monitoring implication: a woman on hormone therapy (HT) will have a different sermorelin response than a postmenopausal woman not on HT. IGF-1 targets cannot be copied from male-focused protocols without adjustment.

Cycle Phase Affects IGF-1 Interpretation

IGF-1 varies across the menstrual cycle, rising modestly in the luteal phase. Brabant et al. (1990) documented a 15-20% intra-cycle IGF-1 fluctuation in premenopausal women. If you draw your IGF-1 at a random cycle day, you may misinterpret a dose as working better or worse than it actually is. Draw IGF-1 on days 3 to 5 (early follicular, low-estrogen baseline) or on days 19 to 21 (midluteal) for consistency, and note which phase on every lab slip.

Sermorelin's Effect on Insulin Sensitivity

GH is counter-regulatory to insulin. Sermorelin-driven GH increases can raise fasting glucose and reduce insulin sensitivity. Women with PCOS already have insulin resistance at a higher baseline prevalence (approximately 50-75% of women with PCOS show metabolic syndrome features), making glucose monitoring non-optional in this group. If you have PCOS and are considering sermorelin, your provider should review your fasting insulin and HOMA-IR before starting, not just your fasting glucose.

How Thymosin Alpha-1 Works in the Female Body

Thymosin alpha-1 is a thymic peptide that modulates both innate and adaptive immunity. It promotes differentiation of naive T-cells into regulatory and effector subtypes, and it upregulates toll-like receptor 9 signaling, enhancing antiviral defense.

Sex Differences in Immune Function and Why They Matter Here

Women mount stronger adaptive immune responses than men. This is protective against infections but also underlies women's higher rates of autoimmune disease: approximately 78% of autoimmune disease cases in the United States occur in women. Thymosin alpha-1 promotes immune activation. For most healthy women, the doses used in practice (typically 1.5 mg subcutaneously twice weekly) are unlikely to provoke autoimmunity, but women with a personal or first-degree family history of lupus, rheumatoid arthritis, multiple sclerosis, or thyroiditis should discuss this risk explicitly before starting. The evidence that thymosin alpha-1 causes autoimmune flares is limited to case reports, not controlled data, but the biological plausibility is real.

Perimenopause and Immune Remodeling

The perimenopausal period involves significant immune remodeling driven by fluctuating and declining estrogen. Estrogen receptors are expressed on T-cells, B-cells, and natural killer cells. As estrogen falls, the Th1/Th2 balance shifts. Some providers argue this makes perimenopause a theoretically good time for immune-supportive peptides. That argument is speculative; no trials have tested thymosin alpha-1 in perimenopausal immune outcomes. What is known is that postmenopausal women have higher baseline inflammatory markers, and adding an immune-stimulating agent without baseline inflammatory labs (CRP, ESR, ANA screening if indicated) creates an incomplete picture.

Dosing Protocols in Practice

Because no combination RCT exists, the protocols below reflect compounding pharmacy guidelines and practitioner-reported approaches, not clinical trial data. Treat these as starting points for conversation with your prescriber, not as prescriptions.

Sermorelin Dosing for Women

Standard adult compounded doses range from 100 mcg to 300 mcg subcutaneously at bedtime, timed to coincide with the largest natural GH pulse, which occurs during slow-wave sleep. Some providers start women at 100 mcg to 200 mcg given that baseline GH secretion and estrogen status differ from males used to calibrate these protocols. The Endocrine Society's 2019 clinical practice guideline on GH deficiency in adults recommends starting adult GH replacement at lower doses in women, particularly those not on oral estrogen, because oral estrogen reduces hepatic IGF-1 sensitivity. The same principle applies to sermorelin titration: women on oral estrogen may need higher doses to achieve equivalent IGF-1 targets compared to women on transdermal estrogen or no HT.

Thymosin Alpha-1 Dosing for Women

The doses used in hepatitis trials were 1.6 mg subcutaneously twice weekly for 6 months. Compounded thymosin alpha-1 for wellness purposes is typically 1.5 mg subcutaneously twice weekly, often for 8 to 16 weeks, followed by a break. Whether continuous dosing carries different risks than cycled dosing in women is not known from human data.

Injection Timing When Using Both

Most practitioners separate the two injections. Sermorelin is given at bedtime; thymosin alpha-1 is given in the morning on two non-consecutive days per week. This is logistically simple and avoids mixing compounds in the same syringe, which has not been tested for stability or compatibility.

Safety Monitoring: A Lab-by-Lab Guide

The monitoring framework below is designed specifically for women, accounting for cycle phase, hormonal status, and female-relevant metabolic risks. No published guideline exists for this specific stack; this framework synthesizes Endocrine Society GH monitoring principles, FDA labeling for sermorelin, and thymosin alpha-1 hepatitis trial safety data.

Before You Start (Baseline)

| Lab | Why It Matters for Women | |-----|--------------------------| | IGF-1 (with cycle day noted) | Establishes your personal baseline; age- and sex-specific reference range required | | Fasting glucose + HbA1c | GH is insulin-antagonist; essential in PCOS, prediabetes | | Fasting insulin + HOMA-IR | More sensitive than glucose alone in women with PCOS | | CBC with differential | Thymosin alpha-1 affects lymphocyte subsets | | CMP (liver and kidney function) | Both peptides are cleared renally; liver enzymes needed before thymosin alpha-1 | | TSH + free T4 | GH replacement can unmask central hypothyroidism; also relevant in postpartum thyroiditis | | LH, FSH, estradiol | Hormonal context for IGF-1 interpretation; identifies perimenopausal status | | ANA screen (if personal or family autoimmune history) | Baseline before immune modulation | | CRP, ESR (if inflammatory symptoms) | Baseline inflammation state |

At 6 to 8 Weeks

Draw IGF-1 at the same cycle phase as baseline. Target IGF-1 is typically the upper third of the age-matched normal range, not above the range. Supraphysiologic IGF-1 is associated with increased breast cancer risk in observational studies: a meta-analysis by Renehan et al. In The Lancet (2004) found that women in the highest IGF-1 quartile had an odds ratio of 1.65 for premenopausal breast cancer compared to the lowest quartile. This does not prove sermorelin causes breast cancer, but it is a strong argument for keeping IGF-1 within, not above, the normal range for your age.

Repeat fasting glucose and liver enzymes. Ask your provider about menstrual cycle changes since starting: cycle irregularity is an underreported side effect of GH-axis manipulation and may reflect downstream effects on LH/FSH pulsatility.

At 3 to 6 Months

Full repeat of baseline labs. For women on thymosin alpha-1, add lymphocyte subset panel (CD4, CD8, NK cells) if available, since thymalfasin's mechanism depends on T-cell modulation and this is the most direct evidence that it is doing what is claimed. If your CD4:CD8 ratio was abnormal at baseline for reasons other than the peptide, this context shapes interpretation.

Red Flags That Require Stopping

• IGF-1 above the upper limit of normal for your age group
• New or worsening joint pain, edema, or carpal tunnel symptoms (signs of GH excess)
• Fasting glucose above 100 mg/dL if previously normal, or above 126 mg/dL
• New ANA positivity or rising titer
• Unexplained menstrual cycle changes lasting more than two cycles
• Signs of autoimmune flare in women with pre-existing autoimmune conditions

Pregnancy, Lactation, and Contraception: Read This Section First

Both sermorelin and thymosin alpha-1 are contraindicated in pregnancy. This is not a theoretical concern; it is a practical one, because sermorelin is often prescribed in women of reproductive age who may not be using reliable contraception.

Sermorelin in Pregnancy

Sermorelin is FDA Pregnancy Category C (animal studies showed adverse fetal effects; no adequate human data). The FDA sermorelin prescribing information states that sermorelin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. In practice, most compounding providers and clinicians treating women of reproductive age require a negative pregnancy test before initiating and reliable contraception throughout the course. GH-axis stimulation during organogenesis has unknown effects on fetal development; the precautionary principle applies firmly here.

Thymosin Alpha-1 in Pregnancy

No human safety data exist for thymosin alpha-1 in pregnancy. Thymic peptides are involved in fetal immune tolerance; introducing exogenous thymic signaling molecules during pregnancy carries theoretical risks to fetal immune programming that cannot be quantified from available data. Thymosin alpha-1 should be considered contraindicated in pregnancy until adequate human safety data exist. Women should use reliable contraception throughout any course.

Lactation

Neither compound has been studied in human lactation. Peptides are generally degraded in the gastrointestinal tract, reducing systemic infant exposure from breast milk, but this reasoning does not substitute for actual pharmacokinetic data. Both should be avoided while breastfeeding. If you are postpartum and breastfeeding, discuss the timing of any peptide therapy with your provider after weaning is complete.

Contraception Requirements

Women of reproductive age starting either compound should use a reliable contraceptive method (combined hormonal contraception, progestin-only pill, IUD, or barrier methods used consistently). Note that combined oral contraceptives affect IGF-1 interpretation, as oral estrogen reduces hepatic IGF-1 production. This should be factored into your lab interpretation, not ignored.

Who This Stack May Be Right For (and Who Should Avoid It)

Life Stages Where the Rationale Is Strongest

Perimenopause (ages approximately 40 to 52, irregular cycles, declining estrogen). GH secretion is already declining. Immune remodeling is occurring. If IGF-1 is confirmed below the lower third of the age-matched range and immune function is clinically relevant (recurrent infections, slow recovery), a structured protocol with close monitoring is the most defensible use case. The Endocrine Society notes that GH deficiency in adults causes increased fat mass, reduced lean mass, and reduced quality of life, outcomes that overlap with perimenopausal symptom clusters, though GH deficiency requires formal provocation testing for diagnosis, not just a low-normal IGF-1.

Post-menopause on transdermal estrogen therapy. Women on transdermal (not oral) HT have the most predictable IGF-1 response to sermorelin because transdermal estrogen does not reduce hepatic IGF-1 sensitivity the way oral estrogen does.

Women with documented immune compromise (not autoimmune disease, but hypogammaglobulinemia, post-cancer recovery under specialist supervision) may have a case for thymosin alpha-1, though this should be managed by an immunologist, not a telehealth generalist.

Who Should Avoid This Stack

• Women who are pregnant, trying to conceive, or not using reliable contraception
• Women with personal history of breast cancer or first-degree family history plus elevated lifetime risk (supraphysiologic IGF-1 risk)
• Women with active autoimmune disease, or ANA-positive status with clinical features
• Women with PCOS who have poorly controlled insulin resistance without first addressing metabolic markers
• Women with active thyroid disease, particularly uncontrolled hyperthyroidism or Hashimoto's with fluctuating TSH, until thyroid function is stable
• Women postpartum or currently breastfeeding

Female-Relevant Conditions and This Stack

PCOS

Insulin resistance, androgen excess, and LH/FSH ratio dysregulation already complicate GH-axis signaling in PCOS. GH itself can worsen insulin resistance. A study by Morales et al. (1996) in Fertility and Sterility found that GH administration in women with PCOS increased androgen levels in some subjects. Sermorelin has not been tested in PCOS, but the mechanism suggests caution and mandatory glucose monitoring.

Hashimoto's Thyroiditis and Postpartum Thyroiditis

GH replacement, including sermorelin, can unmask central hypothyroidism. If your TSH is borderline before starting, or if you have a history of postpartum thyroiditis, recheck TSH at 6 to 8 weeks. Thymosin alpha-1 has been studied in autoimmune thyroiditis models in animals, with mixed results; human data specific to Hashimoto's do not exist.

Osteoporosis and Bone Health

GH directly stimulates osteoblast activity and bone turnover. In postmenopausal women with low bone density, some providers theorize that sermorelin could support bone health alongside standard-of-care bisphosphonates or RANKL inhibitors. This is entirely theoretical; no trial has tested this combination. Sermorelin should not replace evidence-based osteoporosis therapy.

What "Clinical Monitoring" Actually Means in Practice

Monitoring is not a formality. "Clinical monitoring" language in peptide consent forms sometimes means nothing more than a symptom check-in. For this stack, monitoring means specific labs drawn at specific cycle phases, with specific stop criteria, reviewed by a provider who understands female GH physiology.

Ask your prescriber four concrete questions:

1. At what IGF-1 value will you reduce my sermorelin dose?
2. At what glucose level will you stop sermorelin?
3. How will you differentiate a thymosin alpha-1 immune response from an autoimmune flare?
4. What cycle day should I draw my IGF-1 on, and will you note it on the lab order?

If your provider cannot answer all four, the monitoring plan is incomplete.

As WomanRx reviewer Maya Okafor, MD, notes: "The most common monitoring mistake I see with peptide stacks in women is drawing IGF-1 at a random cycle day and comparing it to a male-calibrated reference range. You need a timed draw, an age-matched and sex-matched range, and a provider who knows which direction your IGF-1 should move based on your hormonal status. Without that, the lab result tells you very little."

The absence of RCT data in women is not a reason to refuse all engagement with this topic. Women deserve specific, honest guidance, not a blanket refusal followed by no further help. The goal is: know the mechanism, know the gaps, monitor with intent, and keep IGF-1 within your age-matched normal range.